Latest Earnings Results: Q2 '26
Estimated EPS
$0.74
Reported EPS
$0.78
Surprise
+4.97%
Estimated Rev
$1.7B
Reported Rev
$1.74B
Surprise
+2.4%
$EW Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.42 down -26.32% YoY • Reported revenue of $1.74B up 13.63% YoY • Edwards Lifesciences projects 2026 full-year sales growth of 10% to 11% and reaffirms adjusted EPS guidance of $2.95 to $3.05, while expecting Q3 2026 sales between $1.63 and $1.71 billion.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.74 | -- | -- | N/A |
Q2 '26 | $0.74 | $0.78 | 4.97% | BEAT |
Q1 '26 | $0.73 | $0.78 | 6.98% | BEAT |
Q4 '25 | $0.62 | $0.58 | -6.36% | MISSED |
Q3 '25 | $0.60 | $0.67 | 12.39% | BEAT |